Edition:
United Kingdom

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

8.15USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$8.15
Open
$8.10
Day's High
$8.35
Day's Low
$8.00
Volume
100,147
Avg. Vol
19,476
52-wk High
$9.60
52-wk Low
$4.20

Latest Key Developments (Source: Significant Developments)

KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Kindred Biosciences Inc ::KINDREDBIO ANNOUNCES POSITIVE RESULTS FROM PIVOTAL STUDY OF ZIMETA ORAL FOR FEVER IN HORSES.KINDRED BIOSCIENCES INC - ‍BASED ON PRELIMINARY REVIEW OF SAFETY DATA, DRUG ZIMETA APPEARS TO BE WELL TOLERATED ​.KINDRED BIOSCIENCES INC - CO ANTICIPATES SUBMITTING EFFECTIVENESS TECHNICAL SECTION OF NEW ANIMAL DRUG APPLICATION IN EARLY 2018​.  Full Article

Kindred Biosciences posts Q3 loss of $0.29 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Kindred Biosciences Inc :Kindred biosciences announces third quarter 2017 financial results.Q3 loss per share $0.29.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Kindred Biosciences gets approval from FDA for new animal drug application
Tuesday, 4 Oct 2016 

Kindred Biosciences Inc : Kindred Biosciences receives approval of effectiveness technical section from fda for zimeta new animal drug application . Kindredbio is in process of responding to first round of review by fda on safety technical section .Kindred Biosciences Inc says expects approval of Zimeta in first half of 2017 if FDA review process is rapid.  Full Article

Kindred Biosciences submits final major NADA technical section for Safety for Mirataz to FDA
Friday, 30 Sep 2016 

Kindred Biosciences Inc : Kindred Biosciences submits final major New Animal Drug Application technical section for Safety for Mirataz to FDA and launches KindredBio Equine website .In target animal safety study, Mirataz was generally well-tolerated and no significant safety concerns were identified.  Full Article

Kindred Biosciences submits new drug application to FDA
Monday, 22 Aug 2016 

Kindred Biosciences Inc [KIN.O] : Kindred Biosciences submits new animal drug application technical section for effectiveness for mirataz to FDA .Company plans to submit safety technical section in Q3 of 2016.  Full Article

Kindred Biosciences posts Q2 loss per share $0.25
Monday, 8 Aug 2016 

Kindred Biosciences Inc : Kindred Biosciences announces second quarter 2016 financial results . Q2 loss per share $0.25 .For 2016 calendar year company reiterates its previous guidance for operating expenses to be in range of $24 million to $26 million.  Full Article

Kindred Biosciences submits Zimeta (KIND-012) new animal drug application technical section for effectiveness to FDA
Thursday, 11 Feb 2016 

Kindred Biosciences:The submission to FDA of the Effectiveness Technical Section of the New Animal Drug Application (NADA) for Zimeta(tm) (dipyrone injection, KIND-012).Positive topline results from the pivotal field study (KB0120) of Zimeta for the control of pyrexia (fever) in horses were recently reported by the Company.  Full Article

BRIEF-KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral

* KINDREDBIO ANNOUNCES POSITIVE RESULTS FROM PIVOTAL STUDY OF ZIMETA ORAL FOR FEVER IN HORSES